Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline and Accelerated TMS for Reduction of Nicotine Use
NCT07145866Phase 4Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of d-cycloserine in nicotine dependence (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Biochemically-confirmed continuous nicotine abstinence at 12 weeks, Resting State Functional Connectivity at 12 weeks and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
d-cycloserine
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT07145866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145866.